



## IOL CHEMICALS AND PHARMACEUTICALS LIMITED

<b>National Stock Exchange of India Ltd.</b> Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051	<b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001
<b>Security Symbol: IOLCP</b>	<b>Security Code: 524164</b>

IOLCP/CGC/2020

01<sup>st</sup> August 2020

**Subject: Submission of newspaper publication of audited financial results for the quarter ended 30<sup>th</sup> June 2020**

Dear Sir,

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of the newspaper publication of audited financial results for the quarter ended 30<sup>th</sup> June 2020 published in Economic Times, Business Standard, Financial Express and Punjabi Jagran on 01<sup>st</sup> August 2020.

This is for your information and records.

Thanking You,

Yours faithfully,  
For IOL Chemicals and Pharmaceuticals Limited

  
Abhay Raj Singh  
AVP & Company Secretary



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Pb.) India CIN - L24116PB1986PLC007030  
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com  
Regd. Office: Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India  
Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, INDIA.  
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



## IOL Chemicals and Pharmaceuticals Limited

**KEY HIGHLIGHTS OF RESULTS**

**7%**  
increase  
in  
**EBITDA**  
YoY Growth

**12%**  
increase  
in  
**PBT**  
YoY Growth

**49%**  
increase  
in  
**PAT**  
YoY Growth

### EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

(in ₹ Crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Audited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from operations	465.91	446.81	496.12	1,910.49
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	127.54	90.26	85.32	361.29
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	126.96	90.03	85.32	359.77
6	Equity share capital	58.71	56.89	56.89	56.89
7	Other equity (Reserves excluding revaluation reserve)				756.65
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2020)				
	Basic	22.30	15.87	15.00	63.51
	Diluted	22.30	15.74	15.00	63.38

#### Notes:

- The above is an extract of the detailed format of audited financial results for the quarter ended 30th June, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- Presently, the Company is operating a Metformin Unit with an installed capacity of 4,000 MT per annum. To cater the increase in its demand, the Company successfully set up a new Metformin Unit VII for manufacturing Metformin with the additional capacity of 7,200 MT per annum with capex of ₹ 28 Crore which is funded fully through internal accruals. With this additional capacity, now the total installed capacity of Metformin is 11,200 MT per annum.
- The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 31 July 2020.
- The previous financial quarter / year figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board  
For IOL Chemicals and Pharmaceuticals Limited  
Sd/-

Vijay Garg  
Joint Managing Director  
DIN: 06510248

Place: Ludhiana  
Date: 31 July 2020

CIN: L24116PB1986PLC007030, Regd. Office: Trident Complex, Raikot Road, Barnala-148101, Punjab  
Ph. +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com, www.iolcp.com





## IOL Chemicals and Pharmaceuticals Limited

**KEY HIGHLIGHTS OF RESULTS**



### EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

(in ₹ Crore)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Audited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from operations	465.91	446.81	496.12	1,910.49
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	127.54	90.26	85.32	361.29
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	126.96	90.03	85.32	359.77
6	Equity share capital	58.71	56.89	56.89	56.89
7	Other equity (Reserves excluding revaluation reserve)				756.65
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2020)				
	Basic	22.30	15.87	15.00	63.51
	Diluted	22.30	15.74	15.00	63.38

**Notes:**

- The above is an extract of the detailed format of audited financial results for the quarter ended 30th June, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- Presently, the Company is operating a Metformin Unit with an installed capacity of 4,000 MT per annum. To cater the increase in its demand, the Company successfully set up a new Metformin Unit VII for manufacturing Metformin with the additional capacity of 7,200 MT per annum with capex of ₹ 28 Crore which is funded fully through internal accruals. With this additional capacity, now the total installed capacity of Metformin is 11,200 MT per annum.
- The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 31 July 2020.
- The previous financial quarter / year figures have been regrouped/rearranged/restated wherever considered necessary.

By order of the Board  
For IOL Chemicals and Pharmaceuticals Limited

Sd/-  
Vijay Garg

Joint Managing Director  
DIN: 06510248

Place: Ludhiana  
Date: 31 July 2020

CIN: L24116PB1986PLC007030, Regd. Office: Trident Complex, Raikot Road, Barnala-148101, Punjab  
Ph. +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com, www.iolcp.com



## President Trump's Twitter blocking challenged in new free speech suit

BLOOMBERG  
New York, July 31

**PRESIDENT DONALD TRUMP** was accused of continuing to illegally block critics on Twitter two years after a judge ruled that his account on the social-media platform is a "public forum" and that silencing of detractors was a violation of the First Amendment.

The Knight First Amendment Institute at Columbia University filed a lawsuit Friday on behalf of five people who still can't access the @realDonaldTrump Twitter account, which has 84.4 mil-

lion followers. The complaint also names Trump's deputy chief of staff for communications, Daniel Scavino.

"The president lost this battle more than two years ago when a federal court held that his practice of blocking critics from his Twitter account violates the First Amendment," Katie Falkow, a senior staff attorney at the New York-based institute, said in a statement. "It shouldn't take another lawsuit to get the president to respect the rule of law and to stop blocking people simply because he doesn't like what they're posting."

The White House didn't

immediately respond to a message seeking comment.

Trump uses Twitter regularly to promote his policy agenda, retweet supporters and positive news articles, and to attack his political enemies. On Thursday he used his account to suggest that Election Day be delayed, saying without evidence that mail-in voting will lead to fraud.

The plaintiffs in the new case include freelance writer and blogger Ellen Brodsky, caregiver Daragh Burgess and Donald Moynihan, a professor of public policy at Georgetown University.

## WHO reports record daily increase in global coronavirus cases, up over 292,000

REUTERS  
July 31

**THE WORLD HEALTH ORGANIZATION** reported a record increase in global coronavirus cases on Friday, with the total rising by 292,327.

The biggest increases were from the United States, Brazil, India and South Africa, according to a daily report. Deaths rose by 6,812. The four countries have dominated global headlines with large outbreaks.

The previous WHO record for new cases was 284,196 on July 24. Deaths rose by 9,753 on July 24, the second largest one-day increase ever. Deaths have been averaging 5,200 a day in July, up from an average of 4,600 a day in June.

Nearly 40 countries have reported record single-day increases in coronavirus infections over the last week, around double the number that did so the previous week, according to a Reuters tally showing a pick-up in the

pandemic in every region of the world.

Cases have been on the rise also in Australia, Japan, Hong Kong, Bolivia, Sudan, Ethiopia, Bulgaria, Belgium, Uzbekistan and Israel, among others.

## Sun Pharmaceutical Industries Limited

Regd. Office: SPARC, Sarvaja, Vidyalaya - 390102, Gujarat, INDIA  
Corporate Office: Sun House, Plot No. 201 B1, Western Express Highway, Goregaon (E), Mumbai - 400033  
Tel: +91 22 4324 4324 CIN: L24200GJ1999PLC019090 Website: www.sunpharma.com

Extract of Unaudited Consolidated Financial Results for the Quarter ended June 30, 2020

Particulars	Quarter ended		Year ended	
	30.06.2020 Unaudited	31.03.2020 Audited	30.06.2019 Unaudited	31.03.2020 Audited
Total Income from operations	7,585.23	6,194.39	6,178.39	52,837.50
Net Profit / (Loss) for the period (before Tax, Exceptional items)	1,448.43	838.08	1,647.44	5,270.23
Net Profit / (Loss) for the period before tax (after Exceptional items)	(2,183.90)	577.44	1,647.44	5,099.59
Net Profit / (Loss) after taxes, share of profit / (Loss) of associates and joint venture and non-controlling interests	(1,655.60)	399.94	1,387.48	3,794.93
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(2,055.16)	1,741.44	1,382.76	6,282.79
Equity Share Capital	239.93	239.93	239.93	239.93
Other Equity	N/A	N/A	N/A	45,024.52
Earnings Per Share (of ₹/- each) (not annualised for quarters)				
₹ Basic	(6.90)	1.67	5.73	15.89
₹ Diluted	(6.90)	1.67	5.73	15.89

Notes:  
1. The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2020.

2. Additional information on standalone financial results is as follows:

Particulars	Quarter ended		Year ended	
	30.06.2020 Unaudited	31.03.2020 Audited	30.06.2019 Unaudited	31.03.2020 Audited
Total Income from operations	2,363.04	2,038.08	3,209.01	12,531.83
Net Profit / (Loss) for the period (before Tax, Exceptional items)	531.52	1,187.22	768.14	3,253.00
Net Profit / (Loss) for the period before tax (after Exceptional items)	531.52	1,187.22	768.14	3,253.00
Net Profit / (Loss) for the period after tax (after Exceptional items)	531.95	1,155.85	763.37	3,211.14
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	532.76	1,134.72	755.21	3,130.34

3. The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the Company's website www.sunpharma.com.

For and on behalf of the Board  
Dilip S. Shrivastava  
Managing Director

Mumbai, July 31, 2020



### IOI Chemicals and Pharmaceuticals Limited

**7%**  
Increase in  
EBITDA  
YoY Growth

**12%**  
Increase in  
PBT  
YoY Growth

**48%**  
Increase in  
PAT  
YoY Growth

**EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020** (In ₹ Crore)


Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2020 (Audited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Total Income from operations	465.91	446.81	496.12	1,910.40
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	146.74	130.08	131.02	533.24
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	127.54	90.26	85.32	361.29
5	Total Comprehensive Income for the period (comprising profit/loss) for the period (after tax) and other comprehensive income (after tax)	126.96	90.03	85.32	359.77
6	Equity share capital	56.71	56.89	56.89	56.89
7	Other equity (Reserves excluding revaluation reserve)				756.65
8	Earning per share (of ₹10/- each) (for continuing and discontinued operations) (not annualised except for year ended 31.03.2020)				
	Basic	22.30	15.87	15.00	63.51
	Diluted	22.30	15.74	15.00	63.38

Notes:  
1. The above is an extract of the detailed format of audited financial results for the quarter ended 30th June, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these financial results is available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.ioicp.com.  
2. Presently, the Company is operating a Metformin Unit with an installed capacity of 4,000 MT per annum. To cater the increase in its demand, the Company successfully set up a new Metformin Unit VII for manufacturing Metformin with the additional capacity of 7,200 MT per annum with capex of ₹ 28 Crore which is funded fully through internal accruals. With this additional capacity, now the total installed capacity of Metformin is 11,200 MT per annum.  
3. The above results have been reviewed by the Audit & Risk Management Committee and thereafter approved by the Board of Directors in their respective meetings held on 31 July 2020.  
4. The previous financial quarter / year figures have been regrouped/rearranged/revised wherever considered necessary.

**By order of the Board**  
**For IOI Chemicals and Pharmaceuticals Limited**  
Sd/-  
Vijay Garg  
Joint Managing Director  
DIN: 06510248

Place: Ludhiana  
Date: 31 July 2020

CIN: L24116PB1986PLC007030, Regd. Office: Trident Complex, Railkot Road, Barnala-148101, Punjab  
Ph: +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@ioicp.com, www.ioicp.com



### JUMPNET

Audited Financial Results For the Quarter And Year Ended March 31, 2020  
(Figures in lakhs, except for earnings per share)

Sl. No.	Particulars	Quarter ended 31/3/2020 (Audited)	Quarter ended 31/3/2019 (Audited)	Year ended 31/3/2020 (Audited)	Year ended 31/3/2019 (Audited)
1	Total income from operations	11,188.67	2,161.55	18,515.83	6,865.03
2	Net profit/(loss) for the period (before tax and exceptional items)	1,990.82	115.32	2,701.96	219.36
3	Net profit/(loss) for the period before tax (after exceptional items)	2,270.05	115.32	(10,387.33)	219.36
4	Net profit/(loss) for the period after tax (after exceptional items)	(2,220.37)	111.99	(11,358.48)	163.06
5	Total comprehensive income for the period	(2,220.37)	111.99	(11,358.48)	163.06
6	Equity Share Capital	4,998.11	4,998.11	4,998.11	4,998.11
7	Reserves (excluding Revaluation Reserve)	-	-	(3,113.89)	8,261.67
8	Basic and Diluted EPS (face value of ₹5 each) (not annualised)	(2.22)	0.11	(11.36)	0.16

Notes:  
1. The above is an extract of the detailed format of quarterly & year ended March 31, 2020 financial results filed with the Bombay Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial result is available on the website of the Company at <https://www.jump.tech> & on the website of the Bombay Stock Exchange Ltd at <https://www.bseindia.com>.  
2. Effective April 1, 2019, the Company has adopted Ind AS 116 - 'Lease'. The application of Ind AS 116 did not have any material impact on the financial results of the Company.  
3. Figures of earlier periods have been regrouped, wherever necessary.

For Jump Networks Limited  
Sd/-  
Harshvardhan Sabharwal  
Managing Director  
DIN: 00069888

Place: Mumbai  
Date: July 31, 2020



## LAKSHAY 2021

ONE TEAM, ONE DREAM

Operating Profit  
1223 Cr

CRR  
11.85%

NI  
1257 Cr

PCR  
86.50%

NNPA  
4.35%

**REVIEWED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020** (In ₹ Lacs)

Sl. No.	Particulars	Quarter Ended 30.06.2020 (Reviewed)	Quarter Ended 31.03.2020 (Audited)	Quarter Ended 30.06.2019 (Reviewed)
1.	Total Income from Operations (Net)	443657	451121	444001
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	4300	1678	-60145
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	4300	1678	-60145
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	2146	1678	-60145
5.	Total Comprehensive Income for the period (comprising Profit/Loss) for the period (after tax) and other comprehensive income (after tax)	NA	NA	NA
6.	Equity Share Capital	991834	991834	736220
7.	Reserves (excluding Revaluation Reserves) as shown in the Balance Sheet of Previous Year	894291	894291	802122
8.	Earning Per Share (of ₹ 10/- each) (for continuing and discontinued operations)			
	a. Basic :	0.62	0.029	-6.079
	b. Diluted :	0.62	0.029	-6.079

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites (BSE: [www.bseindia.com](http://www.bseindia.com) and NSE: [www.nseindia.com](http://www.nseindia.com)), Bank's website ([www.ucobank.com](http://www.ucobank.com))

For UCO Bank  
Sd/-  
Ajay Vyas  
Executive Director

Sd/-  
Abh Kumar Goel  
Managing Director & CEO

Place: Kolkata  
Date: 31st July 2020

www.ucobank.com

**यूको बैंक UCO BANK**  
(एक सार्वजनिक उद्योग) (A Govt. of India Undertaking)

सम्मान आपके विश्वास का Honours Your Trust

Toll Free Help Line No: 1800 274 8123



ਬਾਜ਼ੀਲ

ਪਾਕਿਸਤਾਨ

ਭਾਰਤ

24 ਘੰਟੇ 'ਚ

ਵਿਸ਼ਵ

ਯੂਰਪ

ਅਮਰੀਕਾ

ਬਾਜ਼ੀਲ

ਪਾਕਿਸਤਾਨ

ਭਾਰਤ

## ਦੇ ਦੋਸ਼

ਕੀਤੀ ਹੈ। ਜੇਕਰ ਪੁਲਿਸ ਨੇ ਪੀੜਤ ਨੂੰ ਤਿੰਨ ਦਿਨਾਂ 'ਚ ਇਨਸਾਫ਼ ਨਾ ਦਿੱਤਾ ਤਾਂ 5 ਅਗਸਤ ਨੂੰ ਬਾਣਾ ਸਰਾਏ ਤੋਂ ਖਾਂ ਅੰਗੇ ਧਰਨਾ ਦਿੱਤਾ ਜਾਵੇਗਾ। ਸਬੰਧੀ ਬਾਣਾ ਸਰਾਏ ਅਮਨਤ ਖਾਂ ਦੀ ਬਲਵਿੰਦਰ ਸਿੰਘ ਸੰਧੂ ਨੇ ਕਿਹਾ ਕਿ ਇਸ ਸਿੱਖ ਕਾਲੀ ਨੇ ਪੁਲਿਸ ਕੋਲ ਮਨਿਆਂ ਉਸ ਨੇ ਇਕੱਲਿਆਂ ਨਜ਼ੇ ਦੀ ਹਾਲਤ 'ਚ ਘਟਨਾ ਨੂੰ ਅੰਜਾਮ ਦਿੱਤਾ ਹੈ, ਜਿਸ ਕਰ ਕੇ ਮੁਖੀ ਖ਼ਿਲਾਫ਼ ਕਾਰਵਾਈ ਕੀਤੀ ਗਈ ਹੈ। ਕਿਹਾ ਕਿ ਕਿਸੇ ਵੀ ਕਮਰਵਾਰ ਮੁਲਜ਼ਮ ਸ਼ਿਕਾ ਨਹੀਂ ਜਾਵੇਗਾ।

## ਦੂਜੀ ਕਾਪੀ


ਵੀ ਵਿਅਕਤੀ ਨੂੰ ਨੌਕਰੀ ਦੀ ਪ੍ਰਾਪਤੀ ਕੋਈ ਸਮੱਸਿਆ ਨਹੀਂ ਆਵੇਗੀ। ਦੁਆਰਾ ਇਨ੍ਹਾਂ ਅਰਜ਼ੀਆਂ ਦਾ ਹੁਣ ਹੁਣ ਸਿਰਫ਼ ਤਿੰਨ ਦਿਨਾਂ 'ਚ ਜਾਵੇਗਾ ਤੇ ਕਿਸੇ ਵੀ ਵਿਅਕਤੀ ਨੂੰ ਚੋਰ ਕੱਟਣ ਦੀ ਲੋੜ ਨਹੀਂ ਹੈ। ਸਿਰਫ਼ ਅਨਲਾਈਨ ਪ੍ਰਕਿਰਿਆ ਦੀ ਅਪਲਾਈ ਹੋ ਜਾਵੇਗੀ। ਸਤਕਰਤਾ ਦੁਆਰਾ ਦਰਖਾਸਤ ਦੇਣ ਵੇਲੇ ਵੀ ਫੀਸ ਜਮ੍ਹਾਂ ਕਰਵਾਉਣ ਉਪਰੰਤ ਟੈਕਸਟ ਮੈਸੇਜ ਉਸ ਦੇ ਸੰਬੰਧੀਲ ਜਾਵੇਗਾ, ਜਿਸ ਨਾਲ ਉਹ ਅਪਣੀ ਦਾ ਸਟੇਟਸ ਵੀ ਚੈਕ ਕਰ ਸਕੇਗਾ। ਕਾਰਜ ਲਈ ਕੁਲਦੀਪ ਸਿੰਘ ਭੁੱਲਰ ਸਿੱਖਿਆ ਬੋਰਡ ਅਤੇ ਸੁਰਿੰਦਰ ਸਿੰਘ ਸਟੇਟ ਐਵਾਰਡੀ ਅਧਿਆਪਕ ਨੇ ਆ ਮੰਤਰੀ ਵਿਜੈਇੰਦਰ ਸਿੰਗਲਾ ਤੇ ਅਧਿਕਾਰੀਆਂ ਦਾ ਪੰਨਵਾਦ ਕੀਤਾ।

## ਰਾਕੇਸ਼ ਕੁਮਾਰ ਸੋਧੀ ਰਜਿਸਟਰਾਰ ਜ਼ਿੰਮੇਵਾਰੀ

ਬੀ ਜਾਗਰਣ ਪ੍ਰਤੀਨਿਧ, ਆਲਾ : ਪੰਜਾਬੀ ਯੂਨੀਵਰਸਿਟੀ ਟੱਕੇ ਮਹੀਨੇ ਵਿੱਚ ਦੂਜਾ ਰਜਿਸਟਰਾਰ ਗਿਆ ਹੈ। ਡਾ. ਯੋਗਰਾਜ ਸ਼ਰਮਾ ਜਾਗਰਣ ਸਕੂਲ ਸਿੱਖਿਆ ਬੋਰਡ ਦੇ ਮੈਂਬਰ ਬਣਨ 'ਤੇ ਰਜਿਸਟਰਾਰ ਅਹੁਦਾ ਖ਼ਾਲੀ ਹੋ ਗਿਆ ਸੀ, ਜਿਸ ਆਦ ਉਪ ਫੁਲਪਤੀ ਡਾ. ਬੀਐੱਸ ਟ ਨੇ ਪੱਤਰ ਜਾਰੀ ਕਰਦਿਆਂ ਡਾ. ਰ ਕੁਮਾਰ ਨੂੰ ਰਜਿਸਟਰਾਰ ਦਾ ਵਾਧੂ ਜ਼ਿੰਮੇਵਾਰੀ ਸੌਂਪ ਦਿੱਤਾ ਹੈ। ਡਾ. ਮਨਜੀਤ ਠਿੰਜਰ ਜੁਲਾਈ ਮਹੀਨੇ ਵਿੱਚ ਰਜਿਸਟਰਾਰ ਦੇ ਅਹੁਦੇ ਤੋਂ ਸੇਵਾ ਮੁਕਤ ਜਿਨ੍ਹਾਂ ਤੋਂ ਬਾਅਦ ਡਾ. ਯੋਗਰਾਜ ਨੂੰ ਇਸ ਅਹੁਦੇ ਦੀ ਜ਼ਿੰਮੇਵਾਰੀ ਸੌਂਪ ਦਿੱਤੀ ਗਈ। ਕਰੀਬ 21 ਦਿਨ ਇਸ ਅਹੁਦੇ 'ਤੇ ਡਾ. ਯੋਗਰਾਜ ਨੂੰ ਪੰਜਾਬ ਸਰਕਾਰ ਪੰਜਾਬ ਸਕੂਲ ਸਿੱਖਿਆ ਬੋਰਡ ਦਾ ਮੈਂਬਰ ਨਿਯੁਕਤ ਕਰ ਦਿੱਤਾ ਗਿਆ, ਕਾਰਨ ਯੂਨੀਵਰਸਿਟੀ ਰਜਿਸਟਰਾਰ ਦੀ ਮੁੜ ਖ਼ਾਲੀ ਹੋ ਗਈ ਸੀ।



## ਆਈਓਐਲ ਕੈਮੀਕਲਜ਼ ਐਂਡ ਫਾਰਮਾਸਿਊਟੀਕਲਜ਼ ਲਿਮਟਿਡ



ਮਿਤੀ 30 ਜੂਨ 2020 ਨੂੰ ਖਤਮ ਹੋਈ ਤਿਮਾਰੀ ਵਾਸਤੇ ਆਡਿਟਿਡ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦਾ ਸਾਰ

(ਰੁ. ਕਰੋੜ 'ਚ)

ਲੜੀ ਨੰ.	ਵੇਰਵੇ	ਖਤਮ ਹੋਈ ਤਿਮਾਰੀ			ਖਤਮ ਹੋਇਆ ਸਾਲ
		30.06.2020 (ਆਡਿਟਿਡ)	31.03.2020 (ਆਡਿਟਿਡ)	30.06.2019 (ਆਡਿਟਿਡ)	31.03.2020 (ਆਡਿਟਿਡ)
1	ਅਪਰੇਸ਼ਨਜ਼ ਤੋਂ ਕੁੱਲ ਆਮਦਨ	465.91	446.81	496.12	1,910.49
2	ਅਰਜੇ ਲਈ ਸ਼ੁੱਧ ਲਾਭ (ਟੈਕਸ ਤੋਂ ਪਹਿਲਾਂ, ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ)	146.74	130.08	131.02	533.24
3	ਟੈਕਸ ਤੋਂ ਪਹਿਲਾਂ ਅਰਜੇ ਵਾਸਤੇ ਸ਼ੁੱਧ ਲਾਭ (ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ ਤੋਂ ਬਾਅਦ)	146.74	130.08	131.02	533.24
4	ਟੈਕਸ ਪਿੱਛੋਂ ਅਰਜੇ ਵਾਸਤੇ ਸ਼ੁੱਧ ਲਾਭ (ਐਕਸੈਪਸ਼ਨਲ ਅਤੇ/ਜਾਂ ਵਿਸ਼ੇਸ਼ ਆਈਟਮਾਂ ਤੋਂ ਬਾਅਦ)	127.54	90.26	85.32	361.29
5	ਅਰਜੇ ਵਾਸਤੇ ਕੁੱਲ ਸੰਖੇਪ ਆਮਦਨ (ਲਾਭ/ਹਾਨੀ) ਸ਼ਾਮਲ ਅਰਜੇ ਵਾਸਤੇ (ਟੈਕਸ ਪਿੱਛੋਂ) ਅਤੇ ਹੋਰ ਸੰਖੇਪ ਆਮਦਨ (ਟੈਕਸ ਪਿੱਛੋਂ)	126.96	90.03	85.32	359.77
6	ਇਕੁਇਟੀ ਸ਼ੇਅਰ ਕੈਪਿਟਲ	58.71	56.89	56.89	56.89
7	ਹੋਰ ਇਕੁਇਟੀ (ਰਾਖਵਿਆ ਨੂੰ ਛੱਡ ਕੇ ਮੁੜ ਮੁਲਾਂਕਣ ਰਾਖਵਾ)				756.65
8	ਪ੍ਰਤੀ ਸ਼ੇਅਰ ਆਮਦਨ (ਰੁ. 10/- ਹਰੇਕ ਦਾ) (ਚਾਲੂ ਅਤੇ ਅਣ-ਚਾਲੂ ਅਪਰੇਸ਼ਨਜ਼ ਵਾਸਤੇ) (ਸਲਾਨਾ ਨਹੀਂ ਸਿਵਾਏ ਮਿਤੀ 31.03.2020 ਨੂੰ ਖਤਮ ਹੋਏ ਸਾਲ ਲਈ)				
	ਬੇਸਿਕ	22.30	15.87	15.00	63.51
	ਡਿਊਟਿਡ	22.30	15.74	15.00	63.38

### ਟਿੱਪਣੀਆਂ :

- ਉਪਰੋਕਤ ਐਸਈਓਐਈ (ਲਿਮਿਟਿੰਗ ਚਿਫ਼ਲੀਗੇਸ਼ਨਜ਼ ਅਤੇ ਡਿਸਕਲੋਜ਼ਰ ਰਿਕੂਆਇਰਮੈਂਟਸ) ਰੈਗੂਲੇਸ਼ਨਜ਼, 2015 ਦੇ ਰੈਗੂਲੇਸ਼ਨਜ਼ 33 ਅਧੀਨ ਸਟਾਕ ਐਕਸਚੇਂਜਾਂ ਕੋਲ ਭਰੇ ਗਏ ਮਿਤੀ 30 ਜੂਨ, 2020 ਨੂੰ ਖਤਮ ਹੋਈ ਤਿਮਾਰੀ ਦੇ ਆਡਿਟਿਡ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦੇ ਵਿਸਥਾਰਿਤ ਫਾਰਮੈਟ ਦਾ ਇੱਕਸਾਰ ਹੈ। ਇਨ੍ਹਾਂ ਵਿੱਤੀ ਨਤੀਜਿਆਂ ਦਾ ਪੂਰਾ ਫਾਰਮੈਟ ਸਟਾਕ ਐਕਸਚੇਂਜਾਂ ਦੀਆਂ ਵੈੱਬਸਾਈਟਾਂ ਅਰਥਾਤ [www.bseindia.com](http://www.bseindia.com) ਅਤੇ [www.nseindia.com](http://www.nseindia.com) ਅਤੇ ਕੰਪਨੀ ਦੀ ਵੈੱਬਸਾਈਟ [www.iolcp.com](http://www.iolcp.com) ਉੱਪਰ ਉਪਲਬਧ ਹੈ।
- ਵਰਤਮਾਨ 'ਚ ਕੰਪਨੀ 4,000 ਐਮਟੀ ਪ੍ਰਤੀ ਸਾਲ ਦੀ ਇੱਕ ਸਥਾਪਿਤ ਸਮਰਥਾ ਦੇ ਨਾਲ ਇੱਕ ਮੈਟਫੋਰਮਿਨ ਯੂਨਿਟ ਦਾ ਸੰਚਾਲਨ ਕਰ ਰਹੀ ਹੈ। ਇਸ ਦੀ ਮੰਗ ਵਿੱਚ ਵਾਧੇ ਨੂੰ ਪੂਰਾ ਕਰਨ ਲਈ ਕੰਪਨੀ ਨੇ ਸਫਲਤਾਪੂਰਵਕ ਇੱਕ ਨਵੀਂ ਮੈਟਫੋਰਮਿਨ ਯੂਨਿਟ-VII ਦੀ ਰੁ. ਲਗਭਗ 28 ਕਰੋੜ ਦੀ ਲਾਗਤ ਨਾਲ 7,200 ਐਮਟੀ ਪ੍ਰਤੀ ਸਾਲ ਦੀ ਵਾਧੂ ਸਮਰਥਾ ਦੀ ਪੂਰਤੀ ਲਈ ਮੈਟਫੋਰਮਿਨ ਦੇ ਉਤਪਾਦਨ ਵਾਸਤੇ ਸਫਲਤਾਪੂਰਵਕ ਸਥਾਪਿਤ ਕੀਤਾ ਹੈ, ਜਿਸ ਲਈ ਅੰਦਰੂਨੀ ਸਰੋਤਾਂ ਰਾਹੀਂ ਪੂਰੀ ਮਾਲੀ ਮਦਦ ਦਿੱਤੀ ਗਈ ਹੈ। ਇਸ ਵਾਧੂ ਸਮਰਥਾ ਦੇ ਨਾਲ ਹੁਣ ਮੈਟਫੋਰਮਿਨ ਦੀ ਕੁਲ ਸਥਾਪਿਤ ਸਮਰਥਾ 11,200 ਐਮਟੀ ਪ੍ਰਤੀ ਸਾਲ ਹੈ।
- ਉਕਤ ਨਤੀਜਿਆਂ ਦਾ ਆਡਿਟ ਐਂਡ ਰਿਸਕ ਮੈਨੇਜਮੈਂਟ ਕਮੇਟੀ ਦੁਆਰਾ ਗੰਢਿਊ ਕੀਤਾ ਜਾ ਚੁੱਕਾ ਹੈ ਅਤੇ ਬਾਅਦ 'ਚ ਮਿਤੀ 31 ਜੁਲਾਈ, 2020 ਨੂੰ ਨਿਰਦੇਸ਼ਾਂ ਦੇ ਬੋਰਡ ਦੀ ਹੋਈ ਆਪਣੀ ਮੀਟਿੰਗ ਵਿੱਚ ਪ੍ਰਵਾਨ ਕੀਤੇ ਗਏ ਹਨ।
- ਪਿਛਲੀ ਵਿੱਤੀ ਤਿਮਾਰੀ / ਸਾਲ ਦੇ ਅੰਕੜਿਆਂ ਨੂੰ ਰੀਗਰੂਪਿੰਗ/ਰੀਅਰੇਂਜਿੰਗ/ਰੀਸਟ੍ਰਕਚਰਿੰਗ ਕੀਤਾ ਗਿਆ ਹੈ, ਜਿੱਥੇ ਲਾਜ਼ਮੀ ਸਮਝਿਆ ਗਿਆ ਹੈ।

ਬਾ-ਹੁਕਮ ਬੋਰਡ ਵਾਸਤੇ ਆਈਓਐਲ ਕੈਮੀਕਲਜ਼ ਐਂਡ ਫਾਰਮਾਸਿਊਟੀਕਲਜ਼ ਲਿਮਿਟਿਡ ਸਹੀ/- ਵਿਜੇ ਗਰਗ, ਜਾਇੰਟ ਮੈਨੇਜਿੰਗ ਡਾਇਰੈਕਟਰ ਡੀਆਈਐਨ : 06510248

ਸਥਾਨ : ਲੁਧਿਆਣਾ ਮਿਤੀ : 31 ਜੁਲਾਈ, 2020

CIN: L24116PB1986PLC007030, ਰਜਿ. ਆਫਿਸ : ਟਾਈਡੈਂਟ ਕੰਪਲੈਕਸ, ਰਾਏਕੋਟ ਰੋਡ, ਬਰਨਾਲਾ-148101, ਪੰਜਾਬ ਫੋਨ : +91-1679-244701-07, ਫੈਕਸ : +91-1679-244708, ਈ-ਮੇਲ : [contact@iolcp.com](mailto:contact@iolcp.com), [www.iolcp.com](http://www.iolcp.com)